Sight Sciences, Inc.

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

Sight Sciences announced commercial availability of the OMNI Ultra Surgical System, the latest generation of its implant-free ab interno canaloplasty glaucoma platform, to be showcased at the AAO annual meeting October 9-12 in New Orleans. OMNI Ultra enables single-pass canaloplasty followed by trabeculotomy with TruSync Plus technology and enhanced catheter visualization, targeting all three areas of aqueous outflow resistance for adult primary open-angle glaucoma patients. The company will also preview the Clearance Assistant Plus tool for use with its TearCare dry eye system at the meeting.

•1mo ago

TearCare Becomes the First and Only MGD Treatment Indicated to Improve Meibomian Gland Function in Patients with Evaporative Dry Eye Disease

Sight Sciences announced that the FDA updated the Indications for Use for its TearCare System, making it the first and only treatment indicated to improve meibomian gland function in adult patients with evaporative dry eye disease due to MGD. This label expansion establishes a clinically meaningful endpoint focused on gland function rather than just symptom management, reinforcing the importance of addressing the underlying cause of dry eye disease. CEO Paul Badawi described the update as a landmark moment for the company and the dry eye category, highlighting the commitment to interventional technologies.

•2mo ago

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences reported Q2 revenue of $23.4 million, up 20% year-over-year, driven by an 8% increase in Interventional Glaucoma revenue and a 704% surge in Interventional Dry Eye revenue. The company raised its full-year 2026 revenue guidance to $88 million to $92 million, up from a prior range of $83 million to $89 million, while simultaneously lowering its adjusted operating expense guidance. Operational highlights include FDA 510(k) clearance for the OMNI Ultra Surgical System and expanded coverage from Aetna for implant-free glaucoma procedures affecting approximately 25 million lives.

•2mo ago

Sight Sciences Announces Aetna Coverage for OMNI and SION Surgical Systems

Sight Sciences announced that Aetna updated its Glaucoma Surgery Policy to recognize the OMNI Surgical System and SION Surgical Instrument as medically necessary for the treatment of mild-to-moderate open-angle glaucoma. The coverage policy is retroactive to July 14, 2026, and applies to approximately 25 million total commercial covered lives under Aetna plans. CEO Paul Badawi stated that this milestone establishes broad payer access for canaloplasty and goniotomy enabled by the OMNI and SION technologies across all major national payers.

•2mo ago

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Sight Sciences received FDA 510(k) clearance for its next-generation OMNI Ultra Surgical System, designed for canaloplasty and trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The system features implant-free intervention, single-pass canaloplasty, and TruSync Plus technology, building upon the existing OMNI platform which has been utilized in over 350,000 procedures worldwide. The company is preparing for the U.S. commercial launch of OMNI Ultra, which remains on track for the fourth quarter of 2026.

•2mo ago

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

Sight Sciences reported Q1 revenue of $19.7 million, up 13% year-over-year, driven by growth in both Interventional Glaucoma and Dry Eye segments. The company raised full-year 2026 revenue guidance to $83.0–$89.0 million and announced a final judgment in its patent litigation against Alcon, awarding $55.4 million in past damages and a 10% ongoing royalty. Cash usage improved by 40% to $7.0 million, leaving the company with $85.0 million in cash and equivalents as of quarter-end.

•5mo ago